Evidence map›Paper›PMID 38881778›Full record

ArticleRespiratory medicine case reports2024

Onset of takotsubo syndrome induced by osimertinib in a patient with lung adenocarcinoma.

Shouichi Okamoto, Mariko Shinomiya

Abstract readCase Reports
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shouichi OkamotoDivision of Respiratory Medicine, Saiseikai Ibaraki Hospital, 2-1-45, Mitsukeyama, Ibaraki, Osaka, 567-0035, Japan.
Mariko ShinomiyaDivision of Respiratory Medicine, Saiseikai Ibaraki Hospital, 2-1-45, Mitsukeyama, Ibaraki, Osaka, 567-0035, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cardiotoxicity of osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, has been recently reported when treating EGFR mutation-positive non-small cell lung cancer. In this report, we describe a case of an 81-year-old female patient diagnosed with Takotsubo syndrome (TTS). TTS occurred despite the patient receiving osimertinib retreatment at reduced doses and having no history of cardiac or respiratory disease. The findings of this case suggest that clinicians should consider the possibility of TTS induced by osimertinib.

Indexed as

Epidermal growth factor receptor-tyrosine kinase inhibitorLung cancerOsimertinibTakotsubo syndrome

Identifiers

PMID38881778
PMCPMC11180335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.